Longeveron Reports Q1 2026 Financial Results with Revenue Increase and Net Loss Improvement

Longeveron Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $398,000, a slight increase from $381,000 in the same period of 2025. The revenue consisted of $378,000 from clinical trial activities, which marked a 46% increase compared to the previous year, driven by heightened participant demand for the Bahamas Registry Trial. However, contract manufacturing revenue saw a significant decline of 84%, dropping to $20,000 due to reduced demand from a third-party client. The company recorded a gross profit of $264,000, consistent with the previous year, as the cost of revenues remained stable at $134,000.

The company’s operating expenses decreased to $5.0 million from $5.5 million year-over-year, primarily due to a reduction in general and administrative costs, which fell by 7% to $2.7 million. Research and development expenses also decreased by 8% to $2.3 million, reflecting lower performance-related costs and a non-recurring charge from the previous year. Despite these reductions, Longeveron reported a net loss of $4.7 million for the quarter, a slight improvement from the $5.0 million loss recorded in the first quarter of 2025.

In terms of strategic developments, Longeveron completed a private placement on March 11, 2026, raising approximately $15.9 million through the issuance of Class A common stock and Series A preferred stock. This financing is expected to support the company’s operations into the fourth quarter of 2026. The company also has access to an At-The-Market (ATM) equity financing vehicle, allowing for the potential sale of up to $10.7 million in shares, although this facility is currently under restrictions until June 2026.

Operationally, Longeveron is advancing its lead investigational product candidate, laromestrocel, through clinical trials for several indications, including Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer’s disease. The company is currently conducting the ELPIS II Phase 2b trial for HLHS, with top-line results anticipated in August 2026. The FDA has granted various designations to laromestrocel, including Rare Pediatric Disease Designation and Fast Track Designation, indicating the potential for expedited development and review.

Looking ahead, Longeveron anticipates continued operating losses as it invests in research and development to advance its clinical programs. The company is actively seeking additional financing options to support its operational plans and has expressed the need for further capital to ensure its ongoing viability. As of March 31, 2026, Longeveron reported cash and cash equivalents of $15.8 million, with an accumulated deficit of $137.0 million, underscoring the financial challenges it faces as it navigates the complexities of the biotechnology sector.